(VIANEWS) – Beazer Homes USA (BZH), Silicon Motion Technology Corporation (SIMO), Simulations Plus (SLP) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Beazer Homes USA (BZH)
41.1% sales growth and 14.85% return on equity
Beazer Homes USA, Inc. operates as a homebuilder in the United States. It designs, constructs, and sells single-family and multi-family homes under the Beazer Homes, Gatherings, and Choice Plans names. The company sells its homes through commissioned new home sales counselors and independent brokers in Arizona, California, Nevada, Texas, Delaware, Indiana, Maryland, Tennessee, Virginia, Florida, Georgia, North Carolina, and South Carolina. Beazer Homes USA, Inc. was founded in 1985 and is headquartered in Atlanta, Georgia.
Earnings Per Share
As for profitability, Beazer Homes USA has a trailing twelve months EPS of $5.19.
PE Ratio
Beazer Homes USA has a trailing twelve months price to earnings ratio of 5.49. Meaning, the purchaser of the share is investing $5.49 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.85%.
2. Silicon Motion Technology Corporation (SIMO)
33.3% sales growth and 7.21% return on equity
Silicon Motion Technology Corporation, together with its subsidiaries, designs, develops, and markets NAND flash controllers for solid-state storage devices. It offers controllers for computing-grade solid state drives (SSDs), which are used in PCs and other client devices; enterprise-grade SSDs used in data centers; eMMC and UFS mobile embedded storage for use in smartphones and IoT devices; flash memory cards and flash drives for use in expandable storage; and specialized SSDs that are used in industrial, commercial, and automotive applications. It markets its controllers under the SMI brand; enterprise-grade SSDs under the Shannon Systems brand; and single-chip industrial-grade SSDs under the Ferri SSD, Ferri-eMMC, and Ferri-UFS brands. The company markets and sells its products through direct sales personnel and independent electronics distributors to NAND flash makers, module makers, hyperscalers, and OEMs. It operates in Taiwan, the United States, South Korea, China, Malaysia, Singapore, and internationally. Silicon Motion Technology Corporation was founded in 1995 and is based in Hong Kong, Hong Kong.
Earnings Per Share
As for profitability, Silicon Motion Technology Corporation has a trailing twelve months EPS of $1.58.
PE Ratio
Silicon Motion Technology Corporation has a trailing twelve months price to earnings ratio of 46.72. Meaning, the purchaser of the share is investing $46.72 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.21%.
Volume
Today’s last reported volume for Silicon Motion Technology Corporation is 193312 which is 48.66% below its average volume of 376577.
3. Simulations Plus (SLP)
10.7% sales growth and 6.16% return on equity
Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for noncompartmental analysis and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher. In addition, it offers KIWI, a cloud-based web application to organize, process, maintain, and communicate the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for analyzing nonalcoholic fatty liver disease; RENAsym for investigating and predicting drug-induced or acute kidney injury; IPFsym, a software tool to treat or cure idiopathic pulmonary fibrosis; and the Monolix Suite, a solution for modeling and simulation. Further, the company provides population modeling and simulation contract research services; and clinical-pharmacology-based consulting services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. The company was founded in 1996 and is headquartered in Lancaster, California.
Earnings Per Share
As for profitability, Simulations Plus has a trailing twelve months EPS of $0.52.
PE Ratio
Simulations Plus has a trailing twelve months price to earnings ratio of 87.21. Meaning, the purchaser of the share is investing $87.21 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.16%.
Volume
Today’s last reported volume for Simulations Plus is 63117 which is 42.53% below its average volume of 109836.
Moving Average
Simulations Plus’s value is higher than its 50-day moving average of $43.74 and above its 200-day moving average of $42.26.
Revenue Growth
Year-on-year quarterly revenue growth grew by 16.2%, now sitting on 64.67M for the twelve trailing months.
Yearly Top and Bottom Value
Simulations Plus’s stock is valued at $45.35 at 01:22 EST, way under its 52-week high of $52.69 and way above its 52-week low of $32.69.
4. Ormat Technologies (ORA)
9.9% sales growth and 5.94% return on equity
Ormat Technologies, Inc. engages in the geothermal and recovered energy power business in the United States, Indonesia, Kenya, Turkey, Chile, Guadeloupe, Guatemala, Ethiopia, New Zealand, Honduras, and internationally. It operates through three segments: Electricity, Product, and Energy Storage. The Electricity segment develops, builds, owns, and operates geothermal, solar photovoltaic, and recovered energy-based power plants; and sells electricity. The Product segment designs, manufactures, and sells equipment for geothermal, recovered energy-based electricity generation; and provides services relating to the engineering, procurement, construction, operation, and maintenance of geothermal and recovered energy-based power plants. The Product segment serves contractors; developers, owners, and operators of geothermal power plants; and owners and operators of interstate natural gas pipelines, gas processing plants, and cement plants, as well as companies in other energy-intensive industrial processes. The Energy Storage segment offers energy storage and related services, as well as services relating to the engineering, procurement, construction, operation, and maintenance of energy storage units. Ormat Technologies, Inc. was founded in 1965 and is based in Reno, Nevada.
Earnings Per Share
As for profitability, Ormat Technologies has a trailing twelve months EPS of $2.08.
PE Ratio
Ormat Technologies has a trailing twelve months price to earnings ratio of 31.11. Meaning, the purchaser of the share is investing $31.11 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.94%.
Moving Average
Ormat Technologies’s value is under its 50-day moving average of $65.01 and under its 200-day moving average of $70.01.
Previous days news about Ormat Technologies(ORA)
- Ormat technologies (ora) lags Q1 earnings and revenue estimates. According to Zacks on Wednesday, 8 May, "While Ormat Technologies has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?"
5. Pacific Gas & Electric Co. (PCG)
9% sales growth and 9.7% return on equity
PG&E Corporation, through its subsidiary, Pacific Gas and Electric Company, engages in the sale and delivery of electricity and natural gas to customers in northern and central California, the United States. It generates electricity using nuclear, hydroelectric, fossil fuel-fired, fuel cell, and photovoltaic sources. The company owns and operates interconnected transmission lines; electric transmission substations, distribution lines, transmission switching substations, and distribution substations; and natural gas transmission, storage, and distribution system consisting of distribution pipelines, backbone and local transmission pipelines, and various storage facilities. It serves residential, commercial, industrial, and agricultural customers, as well as natural gas-fired electric generation facilities. PG&E Corporation was incorporated in 1905 and is based in Oakland, California.
Earnings Per Share
As for profitability, Pacific Gas & Electric Co. has a trailing twelve months EPS of $1.05.
PE Ratio
Pacific Gas & Electric Co. has a trailing twelve months price to earnings ratio of 15.81. Meaning, the purchaser of the share is investing $15.81 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.7%.
Yearly Top and Bottom Value
Pacific Gas & Electric Co.’s stock is valued at $16.60 at 01:22 EST, below its 52-week high of $18.32 and way above its 52-week low of $14.71.
Sales Growth
Pacific Gas & Electric Co.’s sales growth is 10.8% for the ongoing quarter and 9% for the next.
Moving Average
Pacific Gas & Electric Co.’s worth is below its 50-day moving average of $16.64 and below its 200-day moving average of $16.89.
6. ResMed (RMD)
6.2% sales growth and 22.39% return on equity
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, ResMed has a trailing twelve months EPS of $6.05.
PE Ratio
ResMed has a trailing twelve months price to earnings ratio of 30.72. Meaning, the purchaser of the share is investing $30.72 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.39%.
Volume
Today’s last reported volume for ResMed is 533031 which is 47.54% below its average volume of 1016200.
Previous days news about ResMed(RMD)
- According to Zacks on Wednesday, 8 May, "A few other-ranked stocks in the broader medical space that have announced quarterly results are Align Technology, Inc. (ALGN Quick QuoteALGN – Free Report) , ResMed Inc. (RMD Quick QuoteRMD – Free Report) and Boston Scientific Corporation (BSX Quick QuoteBSX – Free Report) ."
- According to Zacks on Wednesday, 8 May, "Some other top-ranked stocks from the broader medical space are Medpace (MEDP Quick QuoteMEDP – Free Report) , ResMed (RMD Quick QuoteRMD – Free Report) and Encompass Health Corporation (EHC Quick QuoteEHC – Free Report) ."
- Zacks.com featured highlights include resmed, booz allen hamilton and kontoor brands. According to Zacks on Thursday, 9 May, "Chicago, IL - May 9, 2024 - Stocks in this week’s article are ResMed (RMD Quick QuoteRMD – Free Report) , Booz Allen Hamilton (BAH Quick QuoteBAH – Free Report) and Kontoor Brands (KTB Quick QuoteKTB – Free Report) ."
- According to Zacks on Wednesday, 8 May, "Some better-ranked stocks from the broader medical space are Medpace (MEDP Quick QuoteMEDP – Free Report) , ResMed (RMD Quick QuoteRMD – Free Report) and Encompass Health Corporation (EHC Quick QuoteEHC – Free Report) ."
- According to Zacks on Wednesday, 8 May, "Some better-ranked stocks from the broader medical space are Medpace (MEDP Quick QuoteMEDP – Free Report) , ResMed (RMD Quick QuoteRMD – Free Report) and Encompass Health Corporation (EHC Quick QuoteEHC – Free Report) ."
